Peritoneal tumor microenvironment of cancers on cancer hallmarks : perspectives of translational medicine /
This book offers a comprehensive exploration of peritoneal tumors and cancer hallmarks, with a focus on translational medicine. Edited by leading experts in cancer research from various international institutions, it delves into the formation and clinical significance of peritoneal cancers, includin...
| Corporate Author: | |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
London :
Academic Press,
2024.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Front Cover
- Peritoneal Tumor Microenvironment of Cancers on Cancer Hallmarks
- Copyright Page
- Contents
- List of Contributors
- Introduction
- 1 What is the tumor microenvironment?
- 1.1 Introduction
- 1.2 Formation of malignant ascites
- 1.3 Immune cells
- 1.4 Fibroblasts and mesenchymal stem cells
- 1.5 Extracellular matrix
- 1.6 Hypoxia and reactive oxygen species
- 1.7 Tumor microenvironment after cancer therapy
- 1.8 Summary
- References
- 2 Clinical significance of peritoneal cancers
- 2.1 Highlights
- 2.2 Introduction
- 2.3 Etiology and epidemiology
- 2.3.1 Subtypes of peritoneal cancers
- 2.3.2 Etiology of peritoneal cancers
- 2.3.3 Pathogenesis of peritoneal cancers
- 2.3.4 Epidemiology of peritoneal cancers
- 2.4 Diagnosis and prognosis
- 2.4.1 Diagnostic symptoms for peritoneal cancers
- 2.4.2 Diagnostic imaging in peritoneal cancers
- 2.4.3 Diagnostic biopsies in peritoneal cancers
- 2.4.4 Staging and prognosis of peritoneal cancers
- 2.5 Therapy and therapy resistance
- 2.5.1 Surgery
- 2.5.2 Systemic chemotherapy
- 2.5.3 Multimodal therapies
- 2.5.4 Targeted therapies
- 2.5.5 Therapy resistance
- 2.6 Summary and perspective
- References
- 3 Tumor microenvironment of peritoneal carcinomatosis: the concept of premetastatic niche altered before tumor implantation
- 3.1 Highlights
- 3.2 Introduction
- 3.3 Peritoneal complex
- 3.3.1 Anatomy
- 3.3.2 Histology
- 3.3.3 Scanning electron microscopy view
- 3.3.4 Physiology
- 3.4 Peritoneal wall as a premetastatic environment
- 3.4.1 Peritoneum and inflammation
- 3.4.2 Peritoneum and cancer (macroscopic and microscopic analysis)
- 3.4.2.1 Ovarian cancer cell invasion
- 3.4.2.2 Digestive cancer cell invasion
- 3.4.3 Peritoneal liquid in carcinomatosis
- 3.4.3.1 Noncoagulability ascites character
- 3.4.3.1.1 Cytokine array analysis.
- 3.4.3.1.2 Immune cell analysis
- 3.4.4 Peritoneal wall modification during cancer cell implantation
- 3.4.4.1 Mesothelial cell transformation (EMT)
- 3.4.4.2 The submesothelial layer is a target for cancer cells (microscopic analysis)
- 3.4.4.3 Fibrin in the peritoneal cavity
- 3.4.4.4 Cluster formation in the peritoneal cavity
- 3.5 Scar zone on the peritoneal surface as a niche for cancer cell implantation (animal model study)
- 3.5.1 Inhibition of cancer cell interaction with the peritoneal surface could be a therapeutic target
- 3.6 Conclusion and perspectives
- References
- 4 Cellular models for peritoneal cancer research
- 4.1 What is peritoneal cancer?
- 4.1.1 Molecular mechanisms of peritoneal seeding
- 4.1.2 Why cellular models for peritoneal cancer research is needed?
- 4.2 Origin of peritoneal carcinoma
- 4.2.1 Primary peritoneal carcinoma
- 4.2.2 Pseudomyxoma peritonei
- 4.2.3 Peritoneal carcinomatosis from gastric cancer
- 4.2.4 Peritoneal carcinomatosis from ovarian cancer
- 4.2.5 Peritoneal carcinomatosis from colorectal cancer
- 4.3 Peritoneal tumor cell line models
- 4.3.1 Cell line models
- 4.3.1.1 Peritoneal metastasis cell line establishment from ascites
- 4.3.1.2 Peritoneal metastasis cell line establishment from omental seeding and matched primary tumor
- 4.4 Fingerprinting
- 4.5 Mycoplasma
- 4.6 Passaging primary cultures and cryopreservation
- 4.7 Removal of contaminating mesothelial cells and fibroblasts from cultures of isolated peritoneal cells
- 4.8 Use of established peritoneal tumor cell lines
- 4.9 3D culture of gastric cancer cell lines derived from ascites
- References
- 5 Metabolism of cancer cells altered in peritoneal tumor microenvironment
- 5.1 Highlights
- 5.2 Introduction
- 5.3 Cellular components of peritoneal tumor microenvironment.
- 5.4 Metabolic crosstalk in the tumor microenvironment
- 5.5 Peritoneal tumor microenvironment and glucose metabolism
- 5.6 Peritoneal tumor microenvironment and lipid metabolism
- 5.7 Peritoneal tumor microenvironment and amino acid metabolism
- 5.8 Metabolic reprogramming and chemoresistance
- 5.9 Therapeutic perspectives
- 5.10 Conclusion
- References
- 6 Cell-to-cell interactions in peritoneal tumor microenvironment
- 6.1 Introduction
- 6.1.1 Peritoneum cavity and mesothelial cells
- 6.1.2 Peritoneal carcinomatosis
- 6.2 Blood and lymphatic vessels
- 6.3 The omentum
- 6.4 Key biological functions of omentum
- 6.4.1 Omentum favors cancer cell implantation
- 6.5 Sequential events carcinomatosis expansion in peritoneal cavity
- 6.5.1 Cancer cell nodule on peritoneal surface
- 6.5.2 Cancer cell cluster and nodule formation
- 6.6 Peritoneal carcinomatosis and immune response
- 6.7 Cancer cell clusters in peritoneal liquid
- 6.8 Hospicells, as a stromal cell-derived from ascites cancer cell clusters
- 6.9 Origin and markers of hospicells
- 6.10 Hospicells in the regulation of angiogenesis
- 6.10.1 Hospicells-associated chemoresistance to chemotherapy for cancer cells via oncological trogocytosis
- 6.10.2 Hospicells in metastasis of cancer cells
- 6.10.3 Cross-talk between hospicells and immune cells within tumor microenvironment
- 6.11 Conclusion and perspective
- References
- 7 Diagnostic, prognostic, and therapeutic biomarkers of ovarian cancer
- 7.1 Introduction
- 7.2 Ovarian tissue markers
- 7.2.1 Dynamin-related protein 1
- 7.2.2 Gelsolin
- 7.2.3 Hexokinase II
- 7.2.4 Phosphatidylinositol 3-kinase/Akt
- 7.2.5 Programmed cell death ligand 1
- 7.2.6 Folate receptor alpha
- 7.3 Genetic tissue markers
- 7.4 Circulatory biomarkers
- 7.4.1 Protein biomarkers
- 7.4.1.1 Cancer antigen 125.
- 7.4.1.2 Human epididymis protein 4
- 7.4.1.3 Other tumor markers
- 7.4.1.4 Plasma gelsolin
- 7.5 Molecular markers
- 7.5.1 MicroRNAs
- 7.5.2 Methylated DNA
- 7.6 Urinary biomarkers
- 7.7 Human epididymis protein 4
- 7.8 Matrix metalloproteinase
- 7.9 Polyamines
- 7.10 MicroRNAs
- 7.11 Eosinophil-derived neurotoxin and osteopontin
- 7.12 Extracellular vesicles as ovarian cancer biomarkers
- 7.13 The role of CT and MRI in the assessment of peritoneal carcinomatosis
- 7.14 Detection of peritoneal carcinomatosis
- 7.15 Prediction of success of cytoreduction
- 7.16 Treatment response assessment after neoadjuvant chemotherapy (NACT)
- 7.17 Positron emission tomography and radiogenomics for ovarian cancer detection and prognosis
- 7.18 Characterization
- 7.19 T staging
- 7.20 N &
- M staging
- 7.21 Detection of recurrence
- 7.22 Prediction of treatment response
- 7.23 Prediction of prognosis
- 7.24 The other tracers for PET imaging
- 7.25 Radiogenomics
- 7.26 Artificial intelligence in ovarian cancer detection and prognosis
- 7.27 Artificial intelligence application in medical imaging and ovarian cancer
- 7.28 Opportunities and challenges
- 7.29 Looking into the future
- 7.30 Summary and conclusions
- References
- 8 Current and future perspectives of xenograft models of human ovarian cancer
- 8.1 Introduction
- 8.2 Intraperitoneal dissemination of human OC cell lines in murine models
- 8.3 Human OC xenograft in murine models
- 8.4 Patient-derived organoid models of OC
- 8.5 Experimental models of tumor neovascularization and progression using the chick embryo chorioallantoic membrane assay
- 8.6 Comparison in characteristics of experimental models for ovarian cancer studies
- 8.7 Conclusion
- References
- 9 Tumor microenvironment and chemoresistance
- 9.1 Introduction.